Media
Media
Welcome to our news page where you can find our latest media releases.
If you are a media professional, please send media inquiries to media@elvium.ca.
British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)
Elvium Life Sciences is pleased to announce the addition of FOQUEST® (methylphenidate hydrochloride controlled release capsules) to the British Columbia1 PharmaCare formulary and First Nations Health Authority (FNHA) Pharmacy Benefit.
Elvium Life Sciences Announces Publication of New Data Analysis from Studies with FOQUEST® Controlled Release Capsules Examining Sleep Quality Outcomes in Adults with ADHD
Elvium Life Sciences Announces Publication of New Data Analysis from Studies with FOQUEST® Controlled Release Capsules Examining Sleep Quality Outcomes in Adults with ADHD Toronto, Ontario, August 25, 2021 – Elvium Life Sciences, an [...]